CN1142793C - 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 - Google Patents

环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 Download PDF

Info

Publication number
CN1142793C
CN1142793C CNB961961554A CN96196155A CN1142793C CN 1142793 C CN1142793 C CN 1142793C CN B961961554 A CNB961961554 A CN B961961554A CN 96196155 A CN96196155 A CN 96196155A CN 1142793 C CN1142793 C CN 1142793C
Authority
CN
China
Prior art keywords
angiotensin
composition
receptor antagonist
epoxy
oct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB961961554A
Other languages
English (en)
Chinese (zh)
Other versions
CN1192697A (zh
Inventor
J��C������ɣ�¶�
J·C·阿勒桑德尔
J·R·舒
R·J·高尔茨斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of CN1192697A publication Critical patent/CN1192697A/zh
Application granted granted Critical
Publication of CN1142793C publication Critical patent/CN1142793C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB961961554A 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰 Expired - Fee Related CN1142793C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48645695A 1995-06-07 1995-06-07
US08/486,456 1995-06-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2004100027960A Division CN1522701A (zh) 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Publications (2)

Publication Number Publication Date
CN1192697A CN1192697A (zh) 1998-09-09
CN1142793C true CN1142793C (zh) 2004-03-24

Family

ID=23931955

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB961961554A Expired - Fee Related CN1142793C (zh) 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
CNA2004100027960A Pending CN1522701A (zh) 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2004100027960A Pending CN1522701A (zh) 1995-06-07 1996-06-05 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰

Country Status (21)

Country Link
US (1) US6653306B1 (enExample)
EP (1) EP0831910B1 (enExample)
JP (1) JPH11507627A (enExample)
KR (1) KR100618466B1 (enExample)
CN (2) CN1142793C (enExample)
AT (1) ATE209047T1 (enExample)
AU (1) AU725689B2 (enExample)
BR (1) BR9609066A (enExample)
CA (1) CA2224079A1 (enExample)
CZ (1) CZ297975B6 (enExample)
DE (1) DE69617235T2 (enExample)
DK (1) DK0831910T3 (enExample)
ES (1) ES2167571T3 (enExample)
IL (1) IL122242A (enExample)
NO (1) NO318184B1 (enExample)
NZ (1) NZ310730A (enExample)
PL (1) PL185150B1 (enExample)
PT (1) PT831910E (enExample)
RO (1) RO118046B1 (enExample)
RU (1) RU2166330C2 (enExample)
WO (1) WO1996040257A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1249682A (zh) * 1997-01-10 2000-04-05 麦克公司 用于治疗有症状的心力哀竭的血管紧张素ⅱ拮抗剂
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
JP2002538172A (ja) * 1999-03-05 2002-11-12 ジー．ディー．サール エルエルシー 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
WO2001087284A2 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase
NZ522953A (en) * 2000-06-22 2005-10-28 Novartis Ag Tablet containing valsartan, microcrystalline cellulose, crospovidone, colloidal anhydrous silica/colloidal silicon dioxide and magnesium stearate
ATE357257T1 (de) * 2000-07-27 2007-04-15 Pharmacia Corp Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
JP2004505060A (ja) * 2000-07-27 2004-02-19 ファルマシア・コーポレーション 炎症関連心臓血管障害を防止するかまたは治療するためのアルドステロンアンタゴニストおよびシクロオキシゲナーゼ−２阻害剤併用療法
US7998986B2 (en) 2001-12-21 2011-08-16 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
DK1487424T3 (da) * 2002-03-15 2007-01-08 Novartis Ag 4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyridin-3-yl)-pyrimidin-2-yl-amino)phenyl-benzamid til behandling af Ang II-medierede sygdomme
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
US20070123498A1 (en) * 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
CN101024643A (zh) * 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114870A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Kinase inhibitors and methods of use
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
AU2009305669A1 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
ES2433225T3 (es) 2009-01-30 2013-12-10 Takeda Pharmaceutical Company Limited Compuesto con anillos condensados y uso del mismo
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
US8980899B2 (en) 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3238722B1 (en) 2011-01-10 2019-03-13 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
WO2013077921A2 (en) 2011-09-02 2013-05-30 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
JP6105594B2 (ja) 2011-09-30 2017-03-29 エンドゥ ファーマシューティカルズ，インコーポレイティド 癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体
JP6130383B2 (ja) 2011-09-30 2017-05-17 エンドゥ ファーマシューティカルズ，インコーポレイティド ピリジン誘導体
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
CA2886240A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
RU2702908C2 (ru) 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3474856B1 (en) 2016-06-24 2022-09-14 Infinity Pharmaceuticals, Inc. Combination therapies
BR112018077075A2 (pt) 2016-06-29 2019-04-30 Universite De Montreal heterociclos de biarilmetila
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
IL325304A (en) 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US12044455B2 (en) 2021-08-20 2024-07-23 Pioneer Family Brands, Inc. Ice shaver with thermally isolated shave deck
US11971205B2 (en) 2021-08-20 2024-04-30 Pioneer Family Brands, Inc. Ice shaver with splash guard
US11982483B2 (en) 2021-08-20 2024-05-14 Pioneer Family Brands, Inc. Ice shaver with multi-link control arm

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
EP0586513A1 (en) * 1991-05-10 1994-03-16 Merck & Co. Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
AU5449194A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
CN1522701A (zh) 2004-08-25
PT831910E (pt) 2002-05-31
CA2224079A1 (en) 1996-12-19
DK0831910T3 (da) 2002-05-21
AU725689B2 (en) 2000-10-19
DE69617235D1 (de) 2002-01-03
DE69617235T2 (de) 2002-07-25
BR9609066A (pt) 1999-01-26
NO318184B1 (no) 2005-02-14
NO975741D0 (no) 1997-12-05
RU2166330C2 (ru) 2001-05-10
CN1192697A (zh) 1998-09-09
WO1996040257A1 (en) 1996-12-19
EP0831910A1 (en) 1998-04-01
US6653306B1 (en) 2003-11-25
CZ385097A3 (cs) 1998-06-17
EP0831910B1 (en) 2001-11-21
IL122242A (en) 2001-07-24
RO118046B1 (ro) 2003-01-30
ES2167571T3 (es) 2002-05-16
KR19990022548A (ko) 1999-03-25
KR100618466B1 (ko) 2006-12-13
NO975741L (no) 1998-01-29
AU6157796A (en) 1996-12-30
PL324001A1 (en) 1998-04-27
PL185150B1 (pl) 2003-03-31
ATE209047T1 (de) 2001-12-15
NZ310730A (en) 2001-01-26
JPH11507627A (ja) 1999-07-06
IL122242A0 (en) 1998-04-05
CZ297975B6 (cs) 2007-05-09

Similar Documents

Publication Publication Date Title
CN1522701A (zh) 环氧-甾族化合物醛甾酮拮抗剂和血管紧张肽ⅱ拮抗剂联合治疗用于治疗充血性心衰
CN1192696A (zh) 用于充血性心力衰竭治疗的螺甾内酯与血管紧张素ⅱ拮抗药组合疗法
US20040053903A1 (en) Method to treat cardiofibrosis with a combination therapy of an angiotensin II antagonist and an epoxy-steroidal aldosterone antagonist
WO1996040256A1 (en) Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone
CN1330556A (zh) 血管紧张肽－转化酶抑制剂和醛固酮拮抗剂用于降低心血管疾病的发病率和死亡率的联合疗法
RU2384346C2 (ru) Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора
CN1658863A (zh) 重症脓毒病预防治疗药物
CN1859924A (zh) 包含选择性ⅰ1咪唑啉受体激动剂和血管紧张素ⅱ受体阻断剂的药物组合物
CN1236763C (zh) 醛固酮拮抗剂在治疗或预防醛固酮介导的致病作用中的用途
CN1824320A (zh) 含有钙通道阻滞剂和b族维生素的药物组合物及其用途
CN1642556A (zh) 醛固酮受体拮抗剂与胆汁酸多价螯合剂的联合
CN1625404A (zh) 用于心血管疾病预防或治疗的醛甾酮受体拮抗剂和α－肾上腺素调节剂的组合治疗
CN1625412A (zh) 预防或治疗心血管疾病的醛甾酮拮抗剂和非－甾族抗炎剂的组合疗法
CN1638777A (zh) 用于预防或治疗炎症相关病症的醛固酮阻滞剂治疗
AU2003202486B2 (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
HK1073076A (en) Aldosterone antagonist and non-steroidal anti-inflammatory agent combination therapy to prevent or treat cardiovascular disorders
CN101065135A (zh) 涉及心力衰竭的组合物和方法
CN1891297A (zh) 含有血管紧张素ⅱ受体拮抗剂和苯氧酸类化合物的药物组合物
Misra Hypertensive Crises: Recognition and Management
CN1642573A (zh) 醛固酮受体拮抗剂和贝酸衍生物的联合用药
HK1040061A (en) Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
HK1060065B (en) Use of an aldosterone antagonist for the treatment or prohpylaxis of aldosteronemediated pathogenic effects
HK1106449A (en) Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
HK1069972A (en) Methods for treatment or prophylaxis of aldosterone-mediated pathogenic effectgs in a subject using an epoxy-steroidal aldosterone antagonist
CN1976722A (zh) 活性物质联合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20040324